In Vivo 18F‐Florzolotau Tau Positron Emission Tomography Imaging in Parkinson's Disease Dementia

Background Tau pathology is observed during autopsy in many patients with Parkinson's disease dementia (PDD). Positron emission tomography (PET) imaging using the tracer 18F‐florzolotau has the potential to capture tau accumulation in the living brain. Objective The aim was to describe the resu...

Full description

Saved in:
Bibliographic Details
Published inMovement disorders Vol. 38; no. 1; pp. 147 - 152
Main Authors Tang, Yilin, Li, Ling, Hu, Tianyu, Jiao, Fangyang, Han, Linlin, Li, Shiyu, Xu, Zhiheng, Fan, Yun, Sun, Yimin, Liu, Fengtao, Yen, Tzu‐Chen, Zuo, Chuantao, Wang, Jian
Format Journal Article
LanguageEnglish
Published Hoboken, USA John Wiley & Sons, Inc 01.01.2023
Wiley Subscription Services, Inc
Subjects
18F‐florzolotau
Autopsy
Cognitive ability
Computed tomography
Dementia
Dementia disorders
Movement disorders
Neurodegenerative diseases
Neuroimaging
Occipital lobe
Parkinson's disease
Parkinson's disease dementia
Pathology
Positron emission tomography
tau PET imaging
Tau protein
Temporal lobe
Tomography
Online AccessGet full text

Cover

More Information
Summary:Background Tau pathology is observed during autopsy in many patients with Parkinson's disease dementia (PDD). Positron emission tomography (PET) imaging using the tracer 18F‐florzolotau has the potential to capture tau accumulation in the living brain. Objective The aim was to describe the results of 18F‐florzolotau PET/CT (computed tomography) imaging in patients with PDD. Methods Ten patients with PDD, 9 with Parkinson's disease with normal cognition (PD‐NC), and 9 age‐matched healthy controls (HCs) were enrolled. Clinical assessments and 18F‐florzolotau PET/CT imaging were performed. Results 18F‐Florzolotau uptake was significantly higher in the cortical regions of patients with PDD compared with both PD‐NC and HCs, especially in the temporal lobe. Notably, 18F‐florzolotau uptake in the occipital lobe of patients with PDD showed a significant correlation with cognitive impairment as reflected by Mini‐Mental State Examination (MMSE) scores. Conclusions 18F‐Florzolotau PET imaging can effectively capture the occurrence of tau pathology in patients with PDD, which was also linked to MMSE scores. © 2022 International Parkinson and Movement Disorder Society.
Bibliography:Corrections added on 02 Dec 2022, after online publication: Affiliation has been revised for Dr. Chuantao Zuo.
Tzu‐Chen Yen is an employee of APRINOIA Therapeutics Co., Ltd, Suzhou, China. All other authors declare that they have no conflicts of interest.
Relevant conflicts of interest/financial disclosures
Funding agencies
This work was financially supported by the Shanghai Municipal Science and Technology Major Project (grants 2018SHZDZX01 and 21S31902200 to J.W.), the National Health Commission of China (grant Pro20211231084249000238 to J.W.), the National Natural Science Foundation of China (grants 82171421 and 91949118 to J.W.; grants 82021002, 81971641, and 81671239 to C.Z.), the Research Project of the Shanghai Health Commission (grant 2020YJZX0111 to C.Z.), and the Clinical Research Plan of SHDC (grant SHDC2020CR1038B to C.Z.).
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ISSN:0885-3185
1531-8257
DOI:10.1002/mds.29273